Santarus Receives New Coverage from Analysts at Ned Davis Research (SNTS)
Stock analysts at Ned Davis Research started coverage on shares of Santarus (NASDAQ:SNTS) in a report issued on Monday, ARN reports. The firm set a “neutral” rating on the stock.
In other Santarus news, VP William C. Denby sold 24,450 shares of Santarus stock on the open market in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $23.03, for a total transaction of $563,083.50. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of other firms have also recently commented on SNTS. Analysts at Leerink Swann downgraded shares of Santarus from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities raised their price target on shares of Santarus from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at Zacks downgraded shares of Santarus from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. They now have a $27.80 price target on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $25.63.
Santarus (NASDAQ:SNTS) traded down 1.97% during mid-day trading on Monday, hitting $21.95. 992,891 shares of the company’s stock traded hands. Santarus has a 52 week low of $8.47 and a 52 week high of $28.10. The stock has a 50-day moving average of $22.88 and a 200-day moving average of $21.69. The company has a market cap of $1.457 billion and a P/E ratio of 15.60.
Santarus (NASDAQ:SNTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The company’s quarterly revenue was up 89.4% on a year-over-year basis.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.